International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10448209
Original Article
Increased Hematocrit Levels in Third Trimester Pregnant Women as a Predictor of Preeclampsia
 ,
 ,
 ,
Published
Dec. 31, 2023
Abstract

Background: Preeclampsia is a high blood pressure disorder diagnosed during pregnancy which is known to be characterized by the sudden onset of hypertension, proteinuria, and other organ failures at 20 weeks of gestational age. Hematocrit levels in pregnant women have been speculated to be a predictor parameter for the incidence of preeclampsia in pregnancy. One of the mechanisms associated as a predictor of preeclampsia is the blood volume ratio which does not increase simultaneously as in pregnant women with normal blood pressure, thereby producing hematocrit levels (HCT) that are relatively greater than the established standards.

Methods: The research method used was case-control, with the primary sample data being the patient's venous blood sample and the secondary data being the patient's medical records. The data collected was a total of 20 samples with a control population of 10 samples of normal pregnant women and a case population of 10 samples of preeclamptic pregnant women. Bivariate analysis uses the Non-Parametric Mann-Whitney Test.

Results: The research showed that the case group had higher hematocrit levels with Asymp. Sig. (2-tailed) which has a value greater than the Mann-Whitney Test significance level (ɑ = 0.05), namely 0.001 > ɑ = 0.05.

Conclusions: This research concluded that there is a significant difference between the hematocrit levels in preeclamptic pregnant women, which are higher when compared to the hematocrit levels in normal pregnant women.

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
2198 Views
9 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved